Merger Notification - Announcement according to § 10 Cartel Act
Bristol-Myers Squibb Company; Mirati Therapeutics, Inc.
BWB/Z-6434
On 24.11.2023 the Austrian Federal Competition Authority was notified of the following merger:
Planned purchase process
Bristol-Myers Squibb Company (USA) intends to acquire all shares in and sole control over Mirati Therapeutics, Inc. (USA).
The concentration concerns pharmaceutical products used in the treatment of non-small cell lung cancer.
ÖNACE Code: Manufacture of basic pharmaceutical products.
Industry sector: C - Verarbeitendes Gewerbe/Herstellung von Waren
Deadline for bringing in an application pursuant to § 11(1) Cartel Act will end on 22.12.2023.
Entrepreneurs whose legal or economic interests are affected by the merger can bring in a written statement at the Federal Competition Authority or the Federal Cartel Prosecutor within 14 days from publication date.
Note: The intervening party has no right to a certain treatment of the statement and will not gain a party position.
Non-prohibition of the merger
The Federal Competition Authority and the Federal Cartel Prosecutor have not applied for examination of the merger by the Cartel Court. The standstill obligation (§ 17 (1) Cartel Act) ends with effect from 23.12.2023 .